Sangamo Therapeutics files Chapter 11 bankruptcy, agrees to asset sales to Lilly and Astellas
Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10989).
$50M$25M